Simon Edvardson1,2, Yoshiko Murakami3, Thi Tuyet Mai Nguyen4, Maher Shahrour5, Anik St-Denis6, Avraham Shaag1, Nadira Damseh5, Françoise Le Deist4,6,7,8, Yenan Bryceson9, Bassam Abu-Libdeh5, Philippe M Campeau4,8, Taroh Kinoshita3, Orly Elpeleg1. 1. Monique and Jacques Roboh Department of Genetic Research, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 2. Pediatric Neurology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 3. WPI Immunology Frontier Research Center and Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan. 4. CHU Sainte-Justine Research Center, University of Montreal, Montreal, Québec, Canada. 5. Department of Pediatrics and Genetics, Makassed Hospital, Al-Quds Medical School, Jerusalem, Israel. 6. Department of Microbiology and Immunology, CHU Sainte Justine, Montreal, Québec, Canada. 7. Department of Microbiology Infectiology and Immunology, University of Montreal, Montreal, Québec, Canada. 8. Department of Pediatrics, University of Montreal, Montreal, Québec, Canada. 9. Department of Medicine, Centre for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Abstract
BACKGROUND: Of our 1400 exome-studied patients, 67% originate from consanguineous families. ∼80% suffer from variable degree of intellectual disability (ID). The search for disease causing genes using homozygosity mapping was progressing slowly until 2010, then markedly accelerated by the introduction of exome analysis. OBJECTIVES: To identify the disease causing mutation(s) in three patients from two unrelated families who suffered from global developmental delay, severe ID and drug-responsive seizure disorder. METHODS: Exome analysis was performed in DNA of the three patients. The identified PIGC variants were generated and transfected into PIGC-defective mouse cells and the restoration of the surface expression of mouse CD90, CD48 and FLAER was assessed using flow cytometry. The expression of these proteins was also studied on the surface of patients' leucocytes. RESULTS: Three PIGC mutations were identified; homozygous p.L189W in one family and compound heterozygosity for p.L212P/p.R21X variants in another. PIGC participates in the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor which tethers proteins to plasma membrane. In cells lacking PIGC protein, which were transfected with each of the PIGC variants, we detected a clear reduction of surface expression of GPI-anchored proteins. Furthermore, analyses of patients' leucocytes showed significant and constant decrease of CD16 surface expression in granulocytes, and moderate decrease of CD14, CD55, CD59 and FLAER levels. CONCLUSIONS: PIGC joins the list of genes in which mutations result in defective biosynthesis of GPI anchoring, manifesting by global developmental delay and seizure disorder. The lack of specific biomarker dictates exome sequencing as the diagnostic procedure of choice in similar patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND: Of our 1400 exome-studied patients, 67% originate from consanguineous families. ∼80% suffer from variable degree of intellectual disability (ID). The search for disease causing genes using homozygosity mapping was progressing slowly until 2010, then markedly accelerated by the introduction of exome analysis. OBJECTIVES: To identify the disease causing mutation(s) in three patients from two unrelated families who suffered from global developmental delay, severe ID and drug-responsive seizure disorder. METHODS: Exome analysis was performed in DNA of the three patients. The identified PIGC variants were generated and transfected into PIGC-defective mouse cells and the restoration of the surface expression of mouseCD90, CD48 and FLAER was assessed using flow cytometry. The expression of these proteins was also studied on the surface of patients' leucocytes. RESULTS: Three PIGC mutations were identified; homozygous p.L189W in one family and compound heterozygosity for p.L212P/p.R21X variants in another. PIGC participates in the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor which tethers proteins to plasma membrane. In cells lacking PIGC protein, which were transfected with each of the PIGC variants, we detected a clear reduction of surface expression of GPI-anchored proteins. Furthermore, analyses of patients' leucocytes showed significant and constant decrease of CD16 surface expression in granulocytes, and moderate decrease of CD14, CD55, CD59 and FLAER levels. CONCLUSIONS:PIGC joins the list of genes in which mutations result in defective biosynthesis of GPI anchoring, manifesting by global developmental delay and seizure disorder. The lack of specific biomarker dictates exome sequencing as the diagnostic procedure of choice in similar patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Thi Tuyet Mai Nguyen; Yoshiko Murakami; Kristen M Wigby; Nissan V Baratang; Justine Rousseau; Anik St-Denis; Jill A Rosenfeld; Stephanie C Laniewski; Julie Jones; Alejandro D Iglesias; Marilyn C Jones; Diane Masser-Frye; Angela E Scheuerle; Denise L Perry; Ryan J Taft; Françoise Le Deist; Miles Thompson; Taroh Kinoshita; Philippe M Campeau Journal: Am J Hum Genet Date: 2018-09-27 Impact factor: 11.025
Authors: Mariska Davids; Minal Menezes; Yiran Guo; Scott D McLean; Hakon Hakonarson; Felicity Collins; Lisa Worgan; Charles J Billington; Irina Maric; Rebecca Okashah Littlejohn; Tito Onyekweli; David R Adams; Cynthia J Tifft; William A Gahl; Lynne A Wolfe; John Christodoulou; May Christine V Malicdan Journal: Mol Genet Metab Date: 2020-02-10 Impact factor: 4.797
Authors: Alexej Knaus; Jean Tori Pantel; Manuela Pendziwiat; Nurulhuda Hajjir; Max Zhao; Tzung-Chien Hsieh; Max Schubach; Yaron Gurovich; Nicole Fleischer; Marten Jäger; Sebastian Köhler; Hiltrud Muhle; Christian Korff; Rikke S Møller; Allan Bayat; Patrick Calvas; Nicolas Chassaing; Hannah Warren; Steven Skinner; Raymond Louie; Christina Evers; Marc Bohn; Hans-Jürgen Christen; Myrthe van den Born; Ewa Obersztyn; Agnieszka Charzewska; Milda Endziniene; Fanny Kortüm; Natasha Brown; Peter N Robinson; Helenius J Schelhaas; Yvonne Weber; Ingo Helbig; Stefan Mundlos; Denise Horn; Peter M Krawitz Journal: Genome Med Date: 2018-01-09 Impact factor: 11.117
Authors: Martin Krenn; Alexej Knaus; Dominik S Westphal; Saskia B Wortmann; Tilman Polster; Friedrich G Woermann; Michael Karenfort; Ertan Mayatepek; Thomas Meitinger; Matias Wagner; Felix Distelmaier Journal: Ann Clin Transl Neurol Date: 2019-04-11 Impact factor: 4.511
Authors: Thi Tuyet Mai Nguyen; Yoshiko Murakami; Eamonn Sheridan; Sophie Ehresmann; Justine Rousseau; Anik St-Denis; Guoliang Chai; Norbert F Ajeawung; Laura Fairbrother; Tyler Reimschisel; Alexandra Bateman; Elizabeth Berry-Kravis; Fan Xia; Jessica Tardif; David A Parry; Clare V Logan; Christine Diggle; Christopher P Bennett; Louise Hattingh; Jill A Rosenfeld; Michael Scott Perry; Michael J Parker; Françoise Le Deist; Maha S Zaki; Erika Ignatius; Pirjo Isohanni; Tuula Lönnqvist; Christopher J Carroll; Colin A Johnson; Joseph G Gleeson; Taroh Kinoshita; Philippe M Campeau Journal: Am J Hum Genet Date: 2017-11-02 Impact factor: 11.025